3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
34
Neoplasms
8
Triple Negative Breast Neoplasms
3
Neoplasm Metastasis
3
HER2-positive Breast Cancer
3
Salivary Gland Neoplasms
2
Pathologic Complete Response
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Hematologic Neoplasms
2
HER2-positive Early Breast Cancer
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Anatomic Stage I Breast Cancer AJCC v8
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Resectable HER2-positive Breast Cancer
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplastic Cells, Circulating
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoproliferative Disorders
1
Lung Neoplasms
1
Liver Neoplasms
1
Hemangiosarcoma
1
Heart Failure
1
Interventions
pembrolizumab
49
Carboplatin
44
Magnetic Resonance Spectroscopy
40
Specimen Handling
39
Pemetrexed
35
Cisplatin
26
Blood Specimen Collection
25
durvalumab
17
Paclitaxel
17
osimertinib
15
Radiosurgery
15
Bevacizumab
15
Radiotherapy
14
Nivolumab
14
Gemcitabine
14
atezolizumab
13
Biopsy
13
Drug Therapy
12
Docetaxel
11
130-nm albumin-bound paclitaxel
11
Immunoglobulin G
10
X-Rays
9
Taxes
9
Standard of Care
9
Practice Guidelines as Topic
9
Educational Status
9
Disulfides
9
tislelizumab
8
Etoposide
8
Cetuximab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Lung Neoplasms
×
pertuzumab
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled